IGF-1 Mimetic Hydrogel for MSC Survival and Local Inflammation Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The intrinsic function of mesenchymal stem cells (MSCs) is often insufficient for targeted disease treatment, and direct administration of soluble growth factors can lead to undesired off-target effects and unintended side effects, such as ectopic bone formation and inflammation, while MSCs transplanted without a biomaterial carrier may escape the target site and cause injury.

Innovation Solution

A hydrogel combining cell-adhesive and IGF-1-mimetic peptides, such as alginate polymer conjugated with cRGD and IGF-1 mimetic peptides, is developed to enhance MSC survival, the secretion of pro-reparative factors, and attenuate inflammatory responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If soluble growth factors are administered to enhance MSC survival and therapeutic function, then MSC survival and therapeutic function are improved, but off-target effects and unintended side effects occur

Engineering Contradiction:

ImproveMSC survivalVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses a biomaterial carrier (hydrogel) as an intermediary to deliver growth factors to MSCs. The carrier system includes a biodegradable matrix that releases growth factors in a controlled manner, preventing direct systemic administration and its associated off-target effects while ensuring the growth factors reach their intended target cells.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent implements local delivery of growth factors through the biomaterial carrier system. The growth factors are released locally at the site of injury or disease, creating a concentrated therapeutic effect only where needed, rather than systemically throughout the body, thereby avoiding off-target effects.

Inventive Principle:

Principle #3Local quality

2Ease of operation

If MSCs are transplanted without a biomaterial carrier to treat disease, then treatment simplicity is maintained, but MSCs escape the target site and cause injury

Engineering Contradiction:

Improvetransplantation simplicityVSAvoidMSC escape and injury

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The biomaterial carrier acts as a protective intermediary between the transplanted MSCs and the host tissue environment. This carrier system provides a temporary protective matrix that prevents MSC escape while maintaining ease of transplantation through a simple injection or implantation procedure.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The biomaterial carrier provides beforehand cushioning by creating a protective matrix before the MSCs are fully integrated into the host tissue. This carrier system prevents MSC migration and escape during the critical initial phase, cushioning against potential injury while maintaining procedural simplicity.

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

3Productivity

If high doses of growth factors are delivered to enhance MSC function, then therapeutic benefit is improved, but harmful off-target effects increase

Engineering Contradiction:

Improvetherapeutic benefitVSAvoidoff-target effects

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The biomaterial carrier serves as a controlled-release intermediary that delivers high concentrations of growth factors locally to MSCs without systemically distributing them. This allows achieving therapeutic benefits through high local doses while avoiding the harmful off-target effects associated with systemic high-dose administration.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent achieves local quality concentration by delivering growth factors directly to the site of injury through the biomaterial carrier. This creates a localized high-concentration environment that maximizes therapeutic benefit to the target area while preventing dispersion to other body regions where off-target effects would occur.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The efficacy of the hydrogel enhances MSC survival and immunomodulatory capabilities, enhancing the ability of these cells to attenuate inflammatory responses.

Implementation Method 1

A hydrogel combining cell-adhesive and IGF-1-mimetic peptides, such as alginate polymer conjugated with cRGD and IGF-1 mimetic peptides, is developed to enhance MSC survival

Methodology Applied

Scientific EffectPeptide-receptor interaction:

Implementation Method 2

soluble factors secreted by MSCs enhance host cell proliferation and migration

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 3

transplanted MSC actively and continuously secrete cytokines, growth factors, and extracellular vesicles

Methodology Applied

Scientific EffectCellular secretion:

Data Source

PatentUS20260000774A1Insulin-Like Growth Factor Mimetic Peptide Modified Materials to Modify Cellular Inflammation

Publication Date: 2026.01.01 WASHINGTON UNIV IN SAINT LOUIS

AI summary

Among the various aspects of the present disclosure is the provision of a hydrogel encompassing cell-adhesive and insulin-like growth factor (IGF)-1 mimetic peptides to enhance mesenchymal stem cells (MSC) survival, the secretion of pro-reparative factors, and the ability of these cells to attenuate inflammatory responses.